Avellino is a precision medicine company specializing in genetic data, diagnostics and therapies. Founded in 2008, Avellino continues to advance genetic testing in eye care with the 2019 launch of AvaGen, the first genetic test to detect risk for keratoconus and the presence of corneal dystrophies. In March of 2020, Avellino pivoted all operations in the US to focus solely on coronavirus testing, creating the ACTS program to help doctors reopen their practices and surgery centers. Avellino has performed nearly 250,000 coronavirus tests across the US. In August, the company reached the 1 million genetic and molecular testing milestone, a testament to the company’s expertise, vision and ability to react quickly to the needs of diverse patient populations.